Literature DB >> 214557

Synthesis and some pharmacological properties of the 23-peptide 15-lysine-secretin-(5--27). Special role of the residue in position 15 in biological activity of the vasoactive intestinal polypeptide.

M Bodansky, S Natarajan, J D Gardner, G M Makhlouf, S I Said.   

Abstract

The 23-peptide 15-lysine-secretin-(5-27) [S(5-27)] was synthesized on an insoluble support. The residue in position 15 of secretin, aspartic acid, was replaced by lysine, which occupies that position in the vasoactive intestinal polypeptide (VIP), a member of the secretin family. The resulting analogue showed increased VIP-like activity on smooth muscle preparations and unaltered secretin-like activity on pancreatic juice secretion in the rat. The affinity of the new analogue was high-affinity secretin receptors in acinar cells from guinea pig pancreas was less than that of S(5-27) but was higher than that of S(5-27) for high-affinity VIP receptors in the same cells.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 214557     DOI: 10.1021/jm00209a018

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Insights into the impact of phenolic residue incorporation at each position along secretin for receptor binding and biological activity.

Authors:  Maoqing Dong; Delia I Pinon; Laurence J Miller
Journal:  Regul Pept       Date:  2012-11-08

Review 2.  Active esters in solid-phase peptide synthesis.

Authors:  M Bodanszky; M A Bednarek
Journal:  J Protein Chem       Date:  1989-08

3.  Lactam constraints provide insights into the receptor-bound conformation of secretin and stabilize a receptor antagonist.

Authors:  Maoqing Dong; Jerez A Te; Xiequn Xu; Jinhui Wang; Delia I Pinon; Laura Storjohann; Andrew J Bordner; Laurence J Miller
Journal:  Biochemistry       Date:  2011-08-30       Impact factor: 3.162

4.  Rational development of a high-affinity secretin receptor antagonist.

Authors:  Maoqing Dong; Kaleeckal G Harikumar; Sweta R Raval; Juliana E Milburn; Carolyn Clark; Rafael Alcala-Torano; Juan C Mobarec; Christopher A Reynolds; Giovanna Ghirlanda; Arthur Christopoulos; Denise Wootten; Patrick M Sexton; Laurence J Miller
Journal:  Biochem Pharmacol       Date:  2020-03-23       Impact factor: 5.858

5.  Predicting the effects of amino acid replacements in peptide hormones on their binding affinities for class B GPCRs and application to the design of secretin receptor antagonists.

Authors:  Jerez A Te; Maoqing Dong; Laurence J Miller; Andrew J Bordner
Journal:  J Comput Aided Mol Des       Date:  2012-05-11       Impact factor: 3.686

6.  Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial.

Authors:  Maria Boesing; Kristin Abig; Michael Brändle; Martin Brutsche; Emanuel Burri; Björn C Frye; Stéphanie Giezendanner; Jan C Grutters; Philippe Haas; Justian Heisler; Fabienne Jaun; Anne B Leuppi-Taegtmeyer; Giorgia Lüthi-Corridori; Joachim Müller-Quernheim; Reto Nüesch; Wolfgang Pohl; Frank Rassouli; Jörg D Leuppi
Journal:  Trials       Date:  2022-09-20       Impact factor: 2.728

7.  Secretin Receptor as a Target in Gastrointestinal Cancer: Expression Analysis and Ligand Development.

Authors:  Anja Klussmeier; Stefan Aurich; Lars Niederstadt; Bertram Wiedenmann; Carsten Grötzinger
Journal:  Biomedicines       Date:  2022-02-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.